EGLN1 (Egl-9 Family Prolyl Hydroxylase 1) encodes Prolyl Hydroxylase 2 (PHD2), the principal oxygen sensor regulating hypoxia-inducible factor-alpha (HIF-α) stability. EGLN1 is the most important prolyl hydroxylase for HIF regulation under physiological conditions and serves as a critical link between cellular oxygen sensing and adaptive gene expression. Variants in EGLN1 cause congenital erythrocytosis (polycythemia) and have been implicated in Alzheimer's disease and Parkinson's disease through dysregulated hypoxia response pathways.
| Property |
Value |
| Gene Symbol |
EGLN1 |
| Full Name |
Egl-9 Family Prolyl Hydroxylase 1 |
| Previous Names |
PHD2, EGLN1, PHD1 |
| Chromosomal Location |
1q42.12 |
| Gene ID |
54583 |
| Ensembl ID |
ENSG00000127837 |
| UniProt ID |
Q9Y2H5 |
| OMIM |
609424 |
¶ Domain Architecture
PHD2 is a ~426 amino acid protein with a catalytic domain and regulatory regions:
- N-terminal domain: Substrate binding and oxygen sensing
- catalytic core: Contains the 2-oxoglutarate (2-OG) binding site
- C-terminal region: Regulatory functions and VHL interaction
PHD2 is a 2-oxoglutarate (2-OG)-dependent dioxygenase that requires:
- Iron (Fe²⁺): Essential cofactor in the active site
- 2-oxoglutarate: Cosubstrate converted to succinate
- Molecular oxygen: Substrate for hydroxylation
- Ascorbate: Reducing agent for iron
The reaction:
HIF-α + O₂ + 2-OG → HIF-α(OH) + succinate + CO₂
PHD2 activity is modulated by:
- Oxygen concentration: Direct sensing mechanism
- Iron availability: Essential cofactor
- 2-OG levels: Metabolic status indicator
- Succinate accumulation: Product inhibition
- Nitric oxide: Negative regulation
- Reactive oxygen species: Oxidative regulation
PHD2 hydroxylates specific proline residues on HIF-α subunits:
- Pro402 (HIF-1α): Major hydroxylation site
- Pro564 (HIF-1α): Secondary site
- Pro405/Pros566 (HIF-2α): Conserved sites
Hydroxylation creates the binding site for the von Hippel-Lindau (VHL) tumor suppressor protein.
¶ VHL Recognition and Degradation
The hydroxylated HIF-α binds to the VHL E3 ubiquitin ligase complex, leading to:
- Polyubiquitination of HIF-α
- Proteasomal degradation
- Prevents transcriptional activation
Under hypoxia, PHD2 activity decreases, HIF-α escapes hydroxylation, dimerizes with HIF-β, and activates hundreds of target genes.
Beyond HIF-α, PHD2 hydroxylated:
- IKKβ: NF-κB pathway regulation
- RBPJ: Notch signaling
- OSTM1: Bone metabolism
EGLN1 is expressed throughout the brain:
- Neurons: High expression in cortical and hippocampal neurons
- Astrocytes: Moderate expression
- Microglia: Variable expression with activation state
- Oligodendrocytes: Lower expression
| Region |
Expression Level |
Functional Implication |
| Cortex |
High |
Cognitive function |
| Hippocampus |
High |
Memory circuits |
| Substantia nigra |
Moderate |
PD relevance |
| Cerebellum |
Moderate |
Motor coordination |
- Kidney: Highest expression (erythropoietin regulation)
- Heart: High (cardiac adaptation)
- Liver: Moderate
- Skeletal muscle: Variable with oxygen supply
HIF is a heterodimeric transcription factor:
- HIF-α subunits: HIF-1α, HIF-2α (EPAS1), HIF-3α
- HIF-β subunit: Constitutively expressed (ARNT)
HIF target genes regulate:
- Angiogenesis: VEGF, FLT1
- Erythropoiesis: EPO
- Metabolism: GLUT1, PDK1
- Cell survival: BNIP3, REDD1
HIF also regulates:
- Mitochondrial dynamics: PGC-1α, mitophagy
- Immune function: Cytokine production
- Stem cell biology: Notch, Wnt pathways
EGLN1 gain-of-function mutations cause:
- Elevated hemoglobin: Increased RBC production
- High hematocrit: Blood viscosity concerns
- Thrombosis risk: Vascular complications
- Secondary polycythemia: Without JAK2 mutation
The mechanism: increased PHD2 activity leads to enhanced HIF degradation, reducing EPO production feedback.
EGLN1/PHD2 is implicated in AD through multiple mechanisms:
- Reduced HIF activity in AD brains despite hypoxia
- Impaired adaptive response to cerebral hypoperfusion
- Accumulation of dysfunctional PHD2
- Aβ inhibits PHD2 function
- Disrupts oxygen sensing in neurons
- Creates vicious cycle of hypoxia response failure
- Impaired HIF-VEGF axis affects angiogenesis
- Reduced vascular maintenance
- Contributes to vascular dysfunction
- PHD2 inhibitors in clinical trials for AD
- Enhancing HIF may protect neurons
- Improving cerebral blood flow
In PD, EGLN1/PHD2 is relevant through:
- Substantia nigra has high metabolic demand
- Limited oxygen supply in PD brain
- Impaired hypoxia response accelerates degeneration
- HIF regulates PGC-1α and mitochondrial biogenesis
- Dysregulated HIF leads to mitochondrial dysfunction
- Energy failure in dopaminergic neurons
- HIF modulates microglial inflammatory responses
- Dysregulated PHD2 affects cytokine production
- May contribute to chronic neuroinflammation
- PHD2 inhibitors show neuroprotection in models
- Enhancing HIF may support dopaminergic survival
- Clinical trials in development
Paradoxically, EGLN1/PHD2 is also relevant in cancer:
- Tumor hypoxia activates HIF
- Promotes angiogenesis and metastasis
- PHD2 as therapeutic target
- Some tumors have EGLN1 mutations
PHD2 senses oxygen through its catalytic mechanism:
- Oxygen-dependent catalysis: Hydroxylation requires O₂
- Fe²⁺ oxidation: Inactivates enzyme under high O₂
- Metabolic coupling: 2-OG levels reflect cellular energy
This directly links oxygen to gene regulation.
PHD2 and mTOR pathway interact:
- mTOR regulates HIF translation
- PHD2 activity affects mTOR signaling
- Feedback loops in neuronal survival
- IKKβ is a PHD2 substrate
- Cross-talk between hypoxia and inflammation
- Implications for neuroinflammation
Dysregulated EGLN1 leads to:
- Altered metabolic adaptation
- Impaired stress response
- Mitochondrial dysfunction
- Increased apoptosis susceptibility
PHD inhibitors are in development for multiple conditions:
- Stimulate endogenous erythropoietin
- Oral administration vs. injections
- In phase 3 trials for CKD anemia
- Inhibit tumor hypoxia response
- Combined with chemotherapy
- In cancer clinical trials
- Balancing HIF activation in different tissues
- Long-term effects of chronic HIF elevation
- Off-target effects
- Delivery to specific brain regions
- Reduced PHD2 expression in cortex
- Impaired HIF activation despite hypoxia
- Correlation with disease severity
- Therapeutic opportunity
- Altered PHD2 in substantia nigra
- Dysregulated HIF response
- May contribute to neuronal loss
- PHD2 as biomarker
- Increased EGLN1 expression
- Role in inflammatory response
- Potential therapeutic target
Egln1 knockout is embryonic lethal:
- Severe anemia
- Cardiac defects
- Impossible to study adult neurons
Neuron-specific deletion shows:
- Enhanced HIF activation
- Reduced infarct size in stroke
- Protection in some neurodegeneration models
- Overexpression of PHD2: impaired hypoxia response
- Dominant negative: constitutive HIF
- Useful for therapeutic screening
EGLN1 testing is indicated for:
- Unexplained polycythemia
- Familial erythrocytosis
- Suspected congenital disorder
- EGLN1 expression as tissue hypoxia marker
- PHD2 activity in disease states
- Potential for disease monitoring
¶ Drug Candidates
- Multiple PHD2 inhibitors in trials
- Brain-penetrant compounds in development
- Combination therapies
- Anemia: Phase 3 completed
- Stroke: Phase 2 ongoing
- Neurodegeneration: Planning stages
- Cell-type specificity: How does EGLN1 function differ across neurons, glia?
- Disease modification: Can EGLN1 modulation alter disease progression?
- Biomarkers: Can EGLN1 serve as a disease biomarker?
- Therapeutic window: What's the optimal level of HIF activation?
- Single-cell analysis: Cell-type specific EGLN1 function
- Spatial transcriptomics: Regional brain patterns
- iPSC models: Patient-specific disease mechanisms
- Gene therapy: Targeting approaches
¶ Interactions and Pathways
| Partner |
Interaction |
Function |
| VHL |
Direct binding |
HIF degradation |
| HIF-1α |
Substrate |
Hydroxylation |
| HIF-2α |
Substrate |
Hydroxylation |
| PHD1/3 |
Redundancy |
Isozyme function |
| FIH1 |
Cofactor sensing |
Asparaginyl hydroxylation |
- HIF pathway: Primary downstream effects
- mTOR pathway: Cross-talk
- NF-κB pathway: Inflammatory regulation
- NOTCH pathway: Developmental regulation